Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare pediatric lysosomal storage disorders. Headquartered in Paramus, New Jersey and founded in 2014, the company concentrates on disease-modifying therapies that target the underlying biology of these severe genetic conditions rather than only managing symptoms. Polaryx Therapeutics’ current pipeline includes orally available small-molecule candidates PLX-200, PLX-300, and PLX-100, which are designed to address core pathological mechanisms common across multiple lysosomal storage disorders. The company operates through a single reportable segment dedicated to lysosomal storage disorders, encompassing preclinical and clinical development activities for its product candidates. Within the healthcare and biotechnology landscape, Polaryx Therapeutics plays a specialized role in the orphan and rare disease space, aiming to serve patient populations with significant unmet medical needs and providing potential therapeutic options where few or no approved treatments currently exist.